New indole and indazole derivatives as potential antimycobacterial agents

  • Violina T. AngelovaEmail author
  • Tania Pencheva
  • Nikolay Vassilev
  • Rumyana Simeonova
  • Georgi Momekov
  • Violeta Valcheva
Original Research


The study reports on the synthesis and in vitro assessment of the antimycobacterial activity of a series of new indole- and indazole-based aroylhydrazones evaluated against Mycobacterium tuberculosis H37Rv. Isoniazide and ethambutol were used as reference drugs. The most active compounds 3a (MIC 0.4412 μM) and 3e (MIC 0.3969 μM) demonstrated excellent antimycobacterial activity, a very low toxicity against the human embryonic kidney cell line HEK-293T and high selectivity index values (SI = 633.49 and SI > 1978.83, respectively). Importantly, the oral administration of compound 3e at the highest dose of 2000 mg/kg b.w. resulted in no mortalities or evidence of adverse effects, implying that compound 3e is nontoxic. The other derivatives with an indole and indazole scaffold also exhibited high antimycobacterial activity with exception of indole derivatives with Br substituents at the 5th position which exhibited activity weaker than that of ethambutol. The molecular docking investigations performed in an enoyl-ACP reductase (InhA) displayed good docking scores and promising insights on possible interactions with the InhA receptor.


Antimycobacterial activity Cytotoxicity Indazole Indole InhA LD50 Molecular docking 



This work was supported by grant contract no. 77./03.05.2018 at Medical Science Council, MU-Sofia, Bulgaria. The authors are grateful to Dr. PT Nedialkov for taking the mass spectra and to Dr. Marin Rogozerov and Dr. Javor Mitkov for the IR spectra. Acknowledgements are due to Stefka Ivanova and our student Nadezda Janakieva for their technical assistance. We would like to thank Rositsa Mihaylova for determining IC50 of the compounds.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were calculated.

Supplementary material

44_2019_2293_MOESM1_ESM.pdf (2.7 mb)
Supplementary Information
44_2019_2293_MOESM2_ESM.jpg (123 kb)
Supplementary Fig.S1
44_2019_2293_MOESM3_ESM.jpg (166 kb)
Supplementary Fig.S2
44_2019_2293_MOESM4_ESM.tif (25 kb)
Supplementary Fig.S3
44_2019_2293_MOESM5_ESM.docx (18 kb)
Supplementary Table S1


  1. Angelova V, Valcheva V, Vassilev N, Buyukliev R, Mihaylova R, Momekov G (2017a) Synthesis, in vitro antiproliferative and antimycobacterial activity of thiazolidine-2, 4-dione and hydantoin derivatives. Bulg Chem Commun 49:643–651Google Scholar
  2. Angelova VT, Valcheva V, Pencheva T, Voynikov Y, Vassilev N, Mihaylova R, Momekov G, Shivachev B (2017b) Synthesis, antimycobacterial activity and docking study of 2-aroyl-[1] benzopyrano [4, 3-c] pyrazol-4 (1H)-one derivatives and related hydrazide-hydrazones. Bioorg Med Chem Lett 27:2996–3002Google Scholar
  3. Angelova VT, Valcheva V, Vassilev NG, Buyukliev R, Momekov G, Dimitrov I, Saso L, Djukic M, Shivachev B (2017b) Antimycobacterial activity of novel hydrazide-hydrazone derivatives with 2H-chromene and coumarin scaffold. Bioorg Med Chem Lett 27:223–227Google Scholar
  4. Ashok D, Gundu S, Aamate VK, Devulapally MG (2018) Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities. Mol diversity 22:769–778CrossRefGoogle Scholar
  5. Campaniço A, Moreira R, Lopes F (2018) Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. Eur J Med Chem 150:525–545CrossRefGoogle Scholar
  6. Cihan-Üstündağ G, Çapan G (2012) Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents. Mol Divers 16:525–539CrossRefGoogle Scholar
  7. Coelho TS, Cantos JB, Bispo ML, Gonçalves RS, Lima CH, Da Silva PE, Souza MV (2012) In vitro anti-mycobacterial activity of (E)-N’-(monosubstituted-benzylidene) isonicotinohydrazide derivatives against isoniazid-resistant strains Infect Dis Rep 4:e13CrossRefGoogle Scholar
  8. da Silva PB, Campos DL, Ribeiro CM, da Silva IC, Pavan FR (2017) New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001–2016). Curr Opin Ther Pat 27:269–282CrossRefGoogle Scholar
  9. Dehestani L, Ahangar N, Hashemi SM, Irannejad H, Masihi PH, Shakiba A, Emami S (2018) Design, synthesis, in vivo and in silico evaluation of phenacyl triazole hydrazones as new anticonvulsant agents. Bioorg Chem 78:119–129CrossRefGoogle Scholar
  10. Elhakeem MA, Taher AT, Abuel-Maaty SM (2015) Synthesis and anti-mycobacterial evaluation of some new isonicotinylhydrazide analogues. Bull Fac Pharm (Cairo Univ) 53:45–52Google Scholar
  11. Faidallah HM, Khan KA, Rostom SA, Asiri AM (2013) Synthesis and in vitro antitumor and antimicrobial activity of some 2,3-diaryl-7-methyl-4,5,6,7-tetrahydroindazole and 3, 3a, 4, 5, 6, 7-hexahydroindazole derivatives. J Enzyme Inhib Med Chem 28:495–508CrossRefGoogle Scholar
  12. Inam A, Siddiqui SM, Macedo TS, Moreira DRM, Leite ACL, Soares MBP, Azam A (2014) Design, synthesis and biological evaluation of 3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propionic acid hydrazones as antiprotozoal agents. Eur J Med Chem 75:67–76CrossRefGoogle Scholar
  13. John SF, Aniemeke E, Ha NP, Chong CR, Gu P, Zhou J, Zhang Y, Graviss EA, Liu JO, Olaleye OA (2016) Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberc (Edinb) 101:S73–S77CrossRefGoogle Scholar
  14. Konstantinov SM, Eibl H, Berger MR (1999) BCR‐ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol 107:365–374CrossRefGoogle Scholar
  15. Malapati P, Krishna VS, Dharmarajan S (2018) Identification and development of novel indazole derivatives as potent bacterial peptidoglycan synthesis inhibitors. Int J Mycobact 7:76CrossRefGoogle Scholar
  16. Martin A, Camacho M, Portaels F, Palomino JC (2003) Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 47:3616–3619CrossRefGoogle Scholar
  17. Martins F, Santos S, Ventura C, Elvas-Leitão R, Santos L, Vitorino S, Reis M, Miranda V, Correia HF, Aires-de-Sousa J (2014) Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. Eur J Med Chem 81:119–138CrossRefGoogle Scholar
  18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefGoogle Scholar
  19. Nateche F, Martin A, Baraka S, Palomino JC, Khaled S, Portaels F (2006) Application of the resazurin microtitre assay for detection of multidrug resistance in Mycobacterium tuberculosis in Algiers. J Med Microbiol 55:857–860CrossRefGoogle Scholar
  20. Negatu DA, Liu JJ, Zimmerman M, Kaya F, Dartois V, Aldrich CC, Gengenbacher M, Dick T (2017) Whole cell screen of fragment library identifies gut microbiota metabolite indole propionic acid as antitubercular. Antimicrob Agents Chemother 62:e01571–17CrossRefGoogle Scholar
  21. North J, Jackson MC (2018) Indole-based therapeutics. U.S. Patent Application No. 15/669,289.Google Scholar
  22. Nyantakyi SA, Li M, Gopal P, Zimmerman M, Dartois V, Gengenbacher M, Dick T, Go M-L (2018) Indolyl Azaspiroketal Mannich bases are potent anti-mycobacterial agents with selective membrane permeabilizing effects and in vivo activity. J Med Chem 61:5733–5750CrossRefGoogle Scholar
  23. Oliveira PF, Guidetti B, Chamayou A, André-Barrès C, Madacki J, Korduláková J, Mori G, Orena BS, Chiarelli LR, Pasca MR (2017) Mechanochemical synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. Molecules 22:1457CrossRefGoogle Scholar
  24. Parlar S, Erzurumlu Y, Ilhan R, Ballar Kırmızıbayrak P, Alptüzün V, Erciyas E (2018) Synthesis and evaluation of pyridinium‐hydrazone derivatives as potential antitumoral agents. Chem Biol Drug Des 92:1198–1205CrossRefGoogle Scholar
  25. Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M (2016) Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis. ACS Infect Dis 3:18–33CrossRefGoogle Scholar
  26. Peng H-N, Ye L-M, Zhang M, Yang Y-C, Zheng J (2018) Synthesis and antimicrobial activity of 3, 4-dihydropyrimidin-2 (1H)-one derivatives containing a hydrazone moiety. Heterocycl Commun 24:113–117CrossRefGoogle Scholar
  27. Poma A, Fontecchio G, Carlucci G, Chichiricco G (2012) Antiinflammatory & anti-allergy agents in medicinal chemistry. Anti-Inflamm Anti-Allergy Agents Med Chem 1:37–51CrossRefGoogle Scholar
  28. Popiołek Ł, Biernasiuk A (2017) New hydrazides and hydrazide‐hydrazones of 2, 3‐dihalogen substituted propionic acids: synthesis and in vitro antimicrobial activity evaluation Chem Biodivers 14:e1700075CrossRefGoogle Scholar
  29. Popiołek Ł, Biernasiuk A, Berecka A, Gumieniczek A, Malm A, Wujec M (2018) New hydrazide–hydrazones of isonicotinic acid: synthesis, lipophilicity and in vitro antimicrobial screening. Chem Biol Drug Des 91:915–923CrossRefGoogle Scholar
  30. Ragavendran JV, Sriram D, Patel SK, Reddy IV, Bharathwajan N, Stables J, Yogeeswari P (2007) Design and synthesis of anticonvulsants from a combined phthalimide–GABA–anilide and hydrazone pharmacophore. Eur J Med Chem 42:146–151CrossRefGoogle Scholar
  31. Ramírez A, Marquina MA (2017) Aspectos clínicos y microbiológicos de las infecciones producidas por el complejo Mycobacterium abscessus. Av En Biomed 6:120–132Google Scholar
  32. Rudavath D, Sreenivasulu R, Raju RR (2018) Synthesis and antitumor evaluation of indole-substituted indole-fused keto hydrazide–hydrazones. J Pharm Res (Mohali, India) 12:42–46Google Scholar
  33. Schlede E, Genschow E, Spielmann H, Stropp G, Kayser D (2005) Oral acute toxic class method: a successful alternative to the oral LD50 test. Regul Toxicol Pharmacol 42:15–23CrossRefGoogle Scholar
  34. Şenkardeş S, Kaushik-Basu N, Durmaz I, Manvar D, Basu A, Atalay R, Küçükgüzel ŞG (2016) Synthesis of novel diflunisal hydrazide–hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors. Eur J Med Chem 108:301–308CrossRefGoogle Scholar
  35. Shirinzadeh H, Altanlar N, Yucel N, Ozden S, Suzen S (2011) Antimicrobial evaluation of indole-containing hydrazone derivatives. Z Naturforsch C 66:340–344CrossRefGoogle Scholar
  36. Velezheva V, Brennan P, Ivanov P, Kornienko A, Lyubimov S, Kazarian K, Nikonenko B, Majorov K, Apt A (2016) Synthesis and antituberculosis activity of indole–pyridine derived hydrazides, hydrazide–hydrazones, and thiosemicarbazones. Bioorg Med Chem Lett 26:978–985CrossRefGoogle Scholar
  37. Vidyacharan S, Adhikari C, Krishna VS, Reshma RS, Sriram D, Sharada DS (2017) A robust synthesis of functionalized 2H-indazoles via solid state melt reaction (SSMR) and their anti-tubercular activity. Bioorg Med Chem Lett 27:1593–1597CrossRefGoogle Scholar
  38. World Health Organization (2018) Global tuberculosis report 2017. World Health Organization, Geneva.Google Scholar
  39. Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go M-L, Dick T (2017) Amphiphilic indole derivatives as antimycobacterial agents: structure–activity relationships and membrane targeting properties. J Med Chem 60:2745–2763CrossRefGoogle Scholar
  40. Yurttaş L, Ertaş M, Cankılıç MY, Demirayak Ş (2017) Synthesis and antimycobacterial activity evaluation of isatin-derived 3-[(4-aryl-2-thiazolyl])hydrazone]-1H-indol-2, 3-diones. Acta Pharm Sci 55:51–58Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Chemistry, Faculty of PharmacyMedical University of SofiaSofiaBulgaria
  2. 2.Institute of Biophysics and Biomedical EngineeringBulgarian Academy of SciencesSofiaBulgaria
  3. 3.Laboratory of Nuclear Magnetic Resonance, Institute of Organic Chemistry with Centre of PhytochemistryBulgarian Academy of SciencesSofiaBulgaria
  4. 4.Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of PharmacyMedical University-SofiaSofiaBulgaria
  5. 5.Institute of MicrobiologyBulgarian Academy of SciencesSofiaBulgaria
  6. 6.In Vitro Laboratory for Evaluation of Biological Activity and ToxicitySofiaBulgaria

Personalised recommendations